Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Common Stock Follow-on Offering	Additional Paid-in Capital	Additional Paid-in Capital Follow-on Offering	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance at Dec. 31, 2019	$ 423,942	$ 11		$ 793,051		$ (601)	$ (368,519)
Beginning balance (in shares) at Dec. 31, 2019		107,648,925
Reclassification of derivative liability to addition paid-in-capital	29,245			29,245
Issuance of common stock in connection with the achievement of a milestone (in shares)		1,111,111
Issuance of common stock in connection with a collaboration agreement	206,699	$ 1		206,698
Issuance of common stock in connection with a collaboration agreement (in shares)		6,626,027
Issuance of common stock for cashless exercise of warrant (in shares)		211,774
Value of shares agreed to purchase	323,214		$ 1		$ 323,213
Issuance of common stock (in shares)			8,214,285
Issuance of common stock in connection with a grant agreement	0
Vesting of restricted common stock	1,435			1,435
Vesting of restricted common stock (in shares)		1,986,250
Exercise of stock options	4,059			4,059
Exercise of stock option (in shares)		1,618,368
Stock-based compensation	27,600			27,600
Other comprehensive loss	(677)					(677)
Net income (loss)	(298,665)						(298,665)
Ending balance at Dec. 31, 2020	716,852	$ 13		1,385,301		(1,278)	(667,184)
Ending balance (in shares) at Dec. 31, 2020		127,416,740
Issuance of common stock in connection with a collaboration agreement	85,213			85,213
Issuance of common stock in connection with a collaboration agreement (in shares)		1,924,927
Issuance of common stock to settle a contingent consideration	1,860			1,860
Issuance of common stock to settle a contingent consideration (in shares)		42,737
Issuance of common stock in connection with a grant agreement	0
Vesting of restricted common stock (in shares)		89,261
Exercise of stock options	13,077			13,077
Exercise of stock option (in shares)		1,622,718
Issuance of common stock under employee stock purchase plan	2,300			2,300
Issuance of common stock under employee stock purchase plan (in shares)		65,021
Stock-based compensation	83,784			83,784
Other comprehensive loss	179					179
Net income (loss)	528,584						528,584
Ending balance at Dec. 31, 2021	$ 1,431,849	$ 13		1,571,535		(1,099)	(138,600)
Ending balance (in shares) at Dec. 31, 2021	131,161,404	131,161,404
Issuance of common stock in connection with a grant agreement	$ 28,462			28,462
Issuance of common stock in connection with a grant agreement (in shares)		881,365
Vesting of restricted common stock (in shares)		349,496
Exercise of stock options	4,534			4,534
Exercise of stock option (in shares)		696,963
Issuance of common stock under employee stock purchase plan	3,222			3,222
Issuance of common stock under employee stock purchase plan (in shares)		147,459
Stock-based compensation	102,082			102,082
Other comprehensive loss	(8,023)					(8,023)
Net income (loss)	515,837						515,837
Ending balance at Dec. 31, 2022	$ 2,077,963	$ 13		$ 1,709,835		$ (9,122)	$ 377,237
Ending balance (in shares) at Dec. 31, 2022	133,236,687	133,236,687